[HTML][HTML] Modern risk stratification of acute myeloid leukemia in 2023: integrating established and emerging prognostic factors
E Boscaro, I Urbino, FM Catania, G Arrigo, C Secreto… - Cancers, 2023 - mdpi.com
Simple Summary Several factors, both patient-and disease-related, are essential to
accurately estimate acute myeloid leukemia (AML) prognosis. The rapidly evolving field …
accurately estimate acute myeloid leukemia (AML) prognosis. The rapidly evolving field …
[HTML][HTML] AML classification in the year 2023: How to avoid a Babylonian confusion of languages
S Huber, C Baer, S Hutter, F Dicker, M Meggendorfer… - Leukemia, 2023 - nature.com
In parallel to the 5th edition of the World Health Organization Classification of
Haematolymphoid Tumours (WHO 2022), an alternative International Consensus …
Haematolymphoid Tumours (WHO 2022), an alternative International Consensus …
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
A Bataller, A Bazinet, CD DiNardo, A Maiti… - Blood …, 2024 - ashpublications.org
Hypomethylating agents (HMAs) and venetoclax (Ven) represent the standard of care for
patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy …
patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy …
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: The UK NCRI AML19 trial
Liposomal daunorubicin and cytarabine (CPX-351) improved overall survival (OS)
compared with 7+ 3 chemotherapy in older patients with secondary acute myeloid leukemia …
compared with 7+ 3 chemotherapy in older patients with secondary acute myeloid leukemia …
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia
Accurate classification and risk stratification are critical for clinical decision making in
patients with acute myeloid leukemia (AML). In the newly proposed World Health …
patients with acute myeloid leukemia (AML). In the newly proposed World Health …
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia
CD123, a subunit of the interleukin-3 receptor, is expressed on∼ 80% of acute myeloid
leukemias (AMLs). Tagraxofusp (TAG), recombinant interleukin-3 fused to a truncated …
leukemias (AMLs). Tagraxofusp (TAG), recombinant interleukin-3 fused to a truncated …
Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS
Y Najima - International Journal of Hematology, 2023 - Springer
Relapse remains the most critical obstacle in treatment by allogeneic hematopoietic stem
cell transplantation (HSCT). Non-relapse mortality has improved annually, but relapse …
cell transplantation (HSCT). Non-relapse mortality has improved annually, but relapse …
Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting
E Attardi, A Savi, B Borsellino, A Piciocchi… - Blood …, 2023 - ashpublications.org
The increasing knowledge of molecular genetics of acute myeloid leukemia (AML)
necessitated the update of previous diagnostic and prognostic schemes, which resulted in …
necessitated the update of previous diagnostic and prognostic schemes, which resulted in …
[HTML][HTML] Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal …
In patients with acute myeloid leukemia (AML) of intermediate-risk (IR) in first remission
(CR1) with no measurable residual disease (MRD negative), the choice of the best …
(CR1) with no measurable residual disease (MRD negative), the choice of the best …
[HTML][HTML] TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations
J DiGennaro, DA Sallman - Acta Haematologica, 2024 - karger.com
Background: Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy
characterized by uncontrolled proliferation and impaired differentiation of myeloid cells in …
characterized by uncontrolled proliferation and impaired differentiation of myeloid cells in …